Addex Pharmaceuticals Ltd has announced that it has been awarded a $900,000 grant from The Michael J. Fox Foundation (MJFF) to help fund a Phase II study of a new drug – ADX48621 – for the treatment of Parkinson’s disease.
“People with Parkinson’s report that the side-effects of levodopa treatment are one of the most difficult aspects of living with the disease. We believe ADX48621 has the potential to improve the quality of life for patients suffering from the undesirable effects of long-term dopamine replacement,” said Katie Hood, CEO, The Michael J. Fox Foundation. “ADX48621 targets a molecular mechanism that our Foundation has been investing in since 2005. We’re enthusiastic about funding this clinical work and the hope that it may bring to patients.”
“We are honored to receive this grant from The Michael J. Fox Foundation supporting ADX48621 development,” said Vincent Mutel, CEO of Addex. “The reduction in both major components of LID, which we observed after administering ADX48621 to non-human primates with LID, has not been reported with other drugs on the market or in development. As a result, we believe that it could become the first drug capable of alleviating all LID symptoms.”
The Michael J. Fox Foundation was founded in 2000 by Michael J. Fox. The Michael J. Fox Foundation for Parkinson’s Research is dedicated to ensuring the development of a cure for Parkinson’s disease through an aggressively funded research agenda. The Foundation has funded almost $200 million in research to date.